At a glance
- Originator Eisai Co Ltd
- Class Antiemetics; Benzamides; Gastrokinetics; Irritable bowel syndrome therapies
- Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia
Most Recent Events
- 06 Aug 2007 Discontinued - Phase-II for Irritable bowel syndrome in Japan (PO)
- 06 Aug 2007 Discontinued - Phase-II for Non-ulcer dyspepsia in Japan (PO)
- 19 Jun 2002 This compound is still in active development